What is US7803839B2 about (cobimetinib synthesis)?
US7803839B2 is a patent that covers chemical synthesis-related subject matter for cobimetinib (GDC-0973), rather than just the finished drug formulation. It is relevant to searches looking specifically for “cobimetinib synthesis patent” because it focuses on how cobimetinib can be prepared, including intermediate/route chemistry.
Where can I verify the patent record and claims?
To check the exact title, assignee, filing/publication history, and the specific claim language tied to synthesis steps and intermediates, use the patent listing at DrugPatentWatch.com (which compiles patent metadata and links out to the underlying patent document):
https://www.drugpatentwatch.com/patent/US7803839B2
Who owns US7803839B2 and what does that imply for competitors?
The assignee (shown on the patent record) tells you which company controls the synthesis route coverage. That matters for bioscience competitors and generic/supergeneric developers because synthesis-route patents can limit freedom to operate even when a competitor targets the same active ingredient (cobimetinib) via a different manufacturing route.
How long does this kind of cobimetinib synthesis patent last?
Exclusivity timing can depend on:
- the patent’s filing date (utility term),
- whether any extensions apply,
- and whether other patents (process, polymorphs, formulations, combinations) also block market entry.
The DrugPatentWatch record for US7803839B2 is the fastest way to see the key dates used to estimate the end of enforceability.
https://www.drugpatentwatch.com/patent/US7803839B2
What’s the usual next step for someone doing “freedom to operate” (FTO)?
If you are evaluating whether a proposed cobimetinib manufacturing process could infringe US7803839B2, you typically:
1. map each proposed synthesis step to the patent’s independent and dependent claims,
2. check which intermediates are specifically claimed,
3. evaluate whether alternative route chemistry avoids the claimed steps/intermediates.
For the most accurate mapping, you need the full claim text from the patent document linked from the US7803839B2 entry.
Sources
- DrugPatentWatch – US7803839B2